TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06533761: Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

Sponsor: Stelexis BioSciences · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 105 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,106,224

Rescue Site Savings

+$722,432

Unlock Full NCT06533761 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06533761 Rescue Dossier →